返回 Agendas
Learning Objective : Following inhalation of AZD1419 by healthy adults, we sought to confirm engagement of the target of AZD1419, Toll-like receptor 9 (TLR9), by assessing increased expression of genes and gene products regulated by TLR9-mediated interferon (IFN) induction in the lung.
Speaker(s)
Clinical Pharmacology – Inhalation of AZD1419 in Healthy Volunteers Elicits a Robust Interferon Gene Signature Response Through Engagement of TLR9
Albert Candia
Dynavax Technologies, United States
Associate Director
Nonclinical Toxicology – Development of Therapeutics for Topically Treatable Diseases Using Cell-Penetrating Asymmetric RNAi Triggers
Nari Shin, MSC
OliX Pharmaceuticals, Korea, Republic of
Nonclinical Toxicology – Pharmacology and Toxicology Evaluation of a Triantennary N-Acetyl Galactsamine(GalNAc)-Conjugated Antisense Oligonucleotide
Scott Henry, PHD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Nonclinical Development
Nonclinical Toxicology – Exposure to siRNA-GalNAc Conjugates in the Test Systems Used in the Standard Test Battery for Genotoxicity
Maja Janas, PHD
Alnylam Pharmaceuticals, United States
Scientist
Novel Oligonucleotide Therapeutics – siRNA Hetero-Conjugates for Highly Efficient Multi-Gene Silencing
Jonathan Brown, PHD
MPEGLA LLC, United States
Biotechnology Research
Oligonucleotide Regulatory Guidance – Points to Consider When Developing Synthetic Oligonucleotides for Submission of CMC Information in the Drug Applications
Rao Kambhampati, PHD
FDA, United States
Senior Chemist, CDER
Trends in Oligonucleotide Toxicology – The Genotoxic Potential of Antisense Oligonucleotides
Amer Saleh, PHD
AstraZeneca Pharmaceuticals LP, United Kingdom
Postdoctoral Scientist